Insider Transaction Report for Arcellx, Inc.

This filing details insider transactions for Arcellx, Inc. (ACLX) on April 28, 2026. Director Behbahani Ali reported dispositions of Arcellx common stock and the cancellation of stock options. These actions are related to the merger agreement with Gilead Sciences, Inc. The common stock dispositions involved 1925 shares directly owned and 2706 shares indirectly owned. Stock options, including those with exercise prices less than the merger's closing amount, were canceled and converted into cash payments and contingent value rights (CVRs). Specifically, 11459 options with an exercise price of $37.94, 8011 options at $51.30, and 9174 options at $63.68 were processed under footnote F3. All reported post-transaction share amounts are zero, indicating the completion of these transactions in connection with the merger.